A small-randomised placebo controlled clinical trial assessed the effects of physostigmine, a cholinesterase inhibitor, on clinical symptoms and brain glucose metabolism in six PSP patients [77]. This evidence concerns the gene BCHE and supranuclear palsy, progressive, 1.